Rani Therapeutics Holdings Stock Current Valuation
| RANI Stock | USD 1.99 0.04 2.05% |
Valuation analysis of Rani Therapeutics helps investors to measure Rani Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -1.75. The current Enterprise Value Multiple is estimated to decrease to -1.75. Fundamental drivers impacting Rani Therapeutics' valuation include:
Price Book 21.2468 | Enterprise Value 69.6 M | Enterprise Value Ebitda (1.42) | Price Sales 313.1706 | Enterprise Value Revenue 84.2765 |
Undervalued
Today
Please note that Rani Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Rani Therapeutics is based on 3 months time horizon. Increasing Rani Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Rani Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rani Stock. However, Rani Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.99 | Real 7.03 | Target 22.25 | Hype 1.95 |
The intrinsic value of Rani Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Rani Therapeutics' stock price.
Estimating the potential upside or downside of Rani Therapeutics Holdings helps investors to forecast how Rani stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rani Therapeutics more accurately as focusing exclusively on Rani Therapeutics' fundamentals will not take into account other important factors: Rani Therapeutics Holdings Company Current Valuation Analysis
Rani Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Rani Therapeutics Current Valuation | 69.62 M |
Most of Rani Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rani Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rani Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Rani Therapeutics is extremely important. It helps to project a fair market value of Rani Stock properly, considering its historical fundamentals such as Current Valuation. Since Rani Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rani Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rani Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Rani Therapeutics Holdings has a Current Valuation of 69.62 M. This is 99.52% lower than that of the Biotechnology sector and 98.5% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.58% higher than that of the company.
Rani Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rani Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics of similar companies.Rani Therapeutics is currently under evaluation in current valuation category among its peers.
Rani Fundamentals
| Return On Equity | -2.25 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 69.62 M | ||||
| Shares Outstanding | 33.31 M | ||||
| Shares Owned By Insiders | 30.61 % | ||||
| Shares Owned By Institutions | 19.58 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Book | 21.25 X | ||||
| Price To Sales | 313.17 X | ||||
| Gross Profit | 2.72 M | ||||
| EBITDA | (65.28 M) | ||||
| Net Income | (33.97 M) | ||||
| Cash And Equivalents | 98.17 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 30.1 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 14.02 X | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (51.24 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Price To Earnings To Growth | 0.68 X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 140 | ||||
| Beta | 0.11 | ||||
| Market Capitalization | 116.52 M | ||||
| Total Asset | 57.92 M | ||||
| Retained Earnings | (72.89 M) | ||||
| Working Capital | 42.86 M | ||||
| Net Asset | 57.92 M |
About Rani Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rani Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:Check out Rani Therapeutics Piotroski F Score and Rani Therapeutics Altman Z Score analysis. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.57) | Return On Equity (2.25) |
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.